Article
Gastroenterology & Hepatology
Jeffrey A. Berinstein, Jessica L. Sheehan, Michael Dias, Elliot M. Berinstein, Calen A. Steiner, Laura A. Johnson, Randolph E. Regal, John I. Allen, Kelly C. Cushing, Ryan W. Stidham, Shrinivas Bishu, Jami A. R. Kinnucan, Shirley A. Cohen-Mekelburg, Akbar K. Waljee, Peter D. R. Higgins
Summary: The study suggests that tofacitinib with concomitant intravenous corticosteroids may reduce the risk of colectomy in ASUC patients, especially with a dosage of 10 mg three times daily. Rates of complications and steroid dependence were similar between the tofacitinib group and controls. Prospective trials are needed to further investigate the safety and optimal dosing of tofacitinib in ASUC patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Helene Hermand, Jeremie H. Lefevre, Conor Shields, Najim Chafai, Clotilde Debove, Laurent Beaugerie, Magali Svrcek, Yann Parc
Summary: The study found that a small proportion of patients undergoing subtotal colectomy may have their diagnosis changed from ulcerative colitis to Crohn's disease postoperatively, with patients with a disease duration of less than 10 years and an initial diagnosis of IBDU being at higher risk for this diagnostic change.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Article
Gastroenterology & Hepatology
Abhishek Bhurwal, Carlos D. Minacapelli, Anish Patel, Hemant Mutneja, Akshay Goel, Ishani Shah, Vikas Bansal, Bhaumik Brahmbhatt, Kiron M. Das
Summary: This study revealed racial and geographical disparities in colectomy rates among hospitalized patients with UC after the introduction of anti-TNF therapy. African American and Hispanic patients had significantly lower colectomy rates compared to White patients, while the western regions of the United States had the highest colectomy rates. Further research is needed to understand the underlying social and biological factors contributing to these disparities.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Pediatrics
Rebecca A. Saberi, Gareth P. Gilna, Cindy Rodriguez, Walter A. Ramsey, Carlos T. Huerta, Christopher F. O'Neil, Joshua P. Parreco, Amber H. Langshaw, Chad M. Thorson, Juan E. Sola, Eduardo A. Perez
Summary: This study compared the morbidity of open versus laparoscopic colectomy or proctocolectomy for pediatric patients with ulcerative colitis using national readmission outcomes. The results showed that laparoscopic surgery was associated with shorter hospital stay, fewer post-operative complications, and improved readmission outcomes.
JOURNAL OF PEDIATRIC SURGERY
(2022)
Article
Gastroenterology & Hepatology
M. E. Stellingwerf, W. A. Bemelman, M. Lowenberg, C. Y. Ponsioen, G. R. D'Haens, S. vanDieren, C. J. Buskens
Summary: Appendectomy in patients with ulcerative colitis is associated with a decreased risk of colectomy and a delay in surgery, but does not significantly impact the risk of colorectal cancer.
COLORECTAL DISEASE
(2021)
Article
Gastroenterology & Hepatology
Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Summary: Through retrospective review of 121 Korean patients with SR-ASUC, it was found that there were no significant differences in the rates of treatment failure and colectomy at 3 months between the CsA and IFX treatment groups. Additionally, prior use of azathioprine and Mayo score at the time of rescue therapy were both associated with treatment failure or colectomy within 3 months.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Brandon K. Chu, Frank I. Scott, Meenakshi Bewtra
Summary: This simulation study suggests that early incorporation of colectomy for patients medically refractory to infliximab and azathioprine combination therapy may lead to better quality of life for patients with steroid-dependent UC. This finding highlights the importance of a combined medical-surgical approach in the treatment of UC.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Gastroenterology & Hepatology
Ohad Atia, Esther Orlanski-Meyer, Rona Lujan, Natan Ledderman, Shira Greenfeld, Revital Kariv, Saleh Daher, Henit Yanai, Yiska Loewenberg Weisband, Hagit Gabay, Eran Matz, Daniel Nevo, Jacob Ollech, Eran Zittan, Eran Israeli, Doron Schwartz, Yehuda Chowers, Iris Dotan, Dan Turner
Summary: During the biologic era, rates of surgeries and steroid-dependency have remained unchanged in patients with UC, while rates of hospitalizations have slightly decreased. Pediatric-onset disease consistently has worse outcomes despite higher utilization of biologics.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Babatunde Olaiya, Benjamin D. Renelus, Mikolaj Filon, Sumona Saha
Summary: In recent years, there has been a decline in the use of total abdominal colectomy (TAC) among ulcerative colitis (UC) patients, with a significant decrease in postoperative mortality rates. Factors such as age, race, admission type, and surgical delay impact postoperative morbidity and mortality rates.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Summary: This study evaluated colectomy incidence rates and risk factors among patients with ulcerative colitis treated with tofacitinib. The results showed that colectomies were infrequent among patients receiving tofacitinib treatment, and all patients who underwent colectomy had additional risk factors.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Delphine Ley, Ariane Leroyer, Claire Dupont, Helene Sarter, Valerie Bertrand, Claire Spyckerelle, Nathalie Guillon, Pauline Wils, Guillaume Savoye, Dominique Turck, Corinne Gower-Rousseau, Mathurin Fumery, Epimad Grp
Summary: This study evaluated the impact of immunosuppressants and antitumor necrosis factor on long-term outcomes of pediatric-onset ulcerative colitis in a large population-based cohort. The results showed a significant decline in the risk of colectomy in pediatric-onset ulcerative colitis patients with an increased use of immunosuppressants and anti-TNF. However, the risk of disease extension and flare-related hospitalization increased.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Atsushi Kohyama, Kazuhiro Watanabe, Akira Sugita, Kitaro Futami, Hiroki Ikeuchi, Ken-ichi Takahashi, Yasuo Suzuki, Kouhei Fukushima
Summary: This study defined and investigated postoperative ulcerative colitis-related severe enteritis (UCRSE), with 0.8% of cases meeting the criteria. Major symptoms included massive intestinal bleeding, high-output stoma, and intestinal perforation. Some patients developed serious complications, required surgery or long-term maintenance therapy.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Multidisciplinary Sciences
Rahel Bianchi, Barry Mamadou-Pathe, Roland von Kanel, Rene Roth, Philipp Schreiner, Jean-Benoit Rossel, Sabine Burk, Babara Dora, Patrizia Kloth, Andreas Rickenbacher, Matthias Turina, Thomas Greuter, Benjamin Misselwitz, Michael Scharl, Gerhard Rogler, Luc Biedermann
Summary: This study examined the impact of ostomy formation on disease progression, psychological well-being, and working capacity in patients with inflammatory bowel disease. The results showed that patients with ostomy had lower disease activity, similar psychological well-being compared to patients without ostomy, and only a modest impact on working capacity.
Review
Medicine, General & Internal
Abel Botelho Quaresma, Fernanda da Silva Barbosa Barauna, Fabio Vieira Teixeira, Rogerio Saad-Hossne, Paulo Gustavo Kotze
Summary: Most studies have not shown increased complication rates after abdominal surgical procedures in UC patients with preoperative exposure to biologics. Further prospective studies are needed to better establish the impact of preoperative biologics on surgical complications in UC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Letter
Gastroenterology & Hepatology
Joshua Quan, Christopher Ma, Remo Panaccione, Lindsay Hracs, Nastaran Sharifi, Michelle Herauf, Ante Makovinovic, Stephanie Coward, Joseph W. Windsor, Lea Caplan, Richard J. M. Ingram, Jamil N. Kanji, Graham Tipples, Jessalyn K. Holodinsky, Charles N. Bernstein, Douglas J. Mahoney, Sasha Bernatsky, Eric Benchimol, Gilaad G. Kaplan
Review
Gastroenterology & Hepatology
Paul Bahnam, Jurij Hanzel, Christopher Ma, Lily Zou, Neeraj Narula, Siddharth Singh, Brennan Kahan, Vipul Jairath
Summary: In clinical trials for inflammatory bowel disease, the efficacy of drug treatment is often overestimated, leading to smaller-than-expected treatment effects. These findings have important implications for trial design and drug development in this field.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Lotus Alphonsus, Theshani A. De Silva, Christopher Ma, John K. MacDonald, Jurij Hanzel, Melanie Beaton, Talat Bessissow, Maia Kayal, Rocio Sedano, Siddharth Singh, Vipul Jairath
Summary: A systematic review evaluated medical therapy for pouchitis treatment and prevention. The effects of vedolizumab and the De Simone formulation were found to be significant, while the effects of other interventions remain uncertain.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Pharmacology & Pharmacy
Sudheer K. Vuyyuru, Lisa M. Shackelton, Jurij Hanzel, Christopher Ma, Vipul Jairath, Brian G. Feagan
Summary: Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, is a group of complex immune-mediated disorders. Targeting the IL-23/Th-17 axis has shown effectiveness in the treatment of these diseases. IL-12/23 inhibitors have been approved for both Crohn's disease and ulcerative colitis, while IL-23p19 antagonists have shown better outcomes in psoriasis patients. Many specific IL-23p19 antagonists are being studied in the treatment of inflammatory bowel disease.
Article
Gastroenterology & Hepatology
Haim Leibovitzh, Sun-Ho Lee, Juan Antonio Raygoza Garay, Osvaldo Espin-Garcia, Mingyue Xue, Anna Neustaeter, Ashleigh Goethel, Hien Q. Huynh, Anne M. Griffiths, Dan Turner, Karen L. Madsen, Paul Moayyedi, A. Hillary Steinhart, Mark S. Silverberg, Colette Deslandres, Alain Bitton, David R. Mack, Kevan Jacobson, Maria Cino, Guy Aumais, Charles N. Bernstein, Remo Panaccione, Batia Weiss, Jonas Halfvarson, Wei Xu, Williams Turpin, Kenneth Croitoru
Summary: This study identified serum proteomic signatures associated with future development of Crohn's disease (CD), reflecting potential early biological processes of immune and barrier dysfunction.
Article
Gastroenterology & Hepatology
Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan
Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione
Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione
Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Multidisciplinary Sciences
Martin A. Prusinkiewicz, Sadaf Sediqi, Ying Jie Li, David M. Goldfarb, Michael Asamoah-Boaheng, Nechelle Wall, Pascal M. Lavoie, Brian Grunau
Summary: This study investigated the impact of the interval between the first and second vaccine doses and between the second and third doses on the immunogenicity of the BNT162b2 vaccine. The results showed that longer intervals between doses were associated with increased immunogenicity. Increasing the interval between the second and third doses up to 8.9 months provided additional benefits in enhancing the immune response.
Review
Health Care Sciences & Services
Lin Yang, Angela Kuang, Claire Xu, Brittany Shewchuk, Shaminder Singh, Hude Quan, Yong Zeng
Summary: The aim of this study is to identify best practices for designing mHealth interventions targeting diet, physical activity, and sedentary behavior. The design characteristics of current mHealth tools, including personalization, real-time functions, and deliverable resources, will be summarized. The findings will serve as a foundation for developing mHealth tools for sustainable behavior change.
JMIR RESEARCH PROTOCOLS
(2023)
Article
Immunology
Jurij Hanzel, Christopher Ma, Vipul Jairath
Summary: Mirikizumab, an IL-23 inhibitor, is an effective and safe drug to treat moderate-to-severe ulcerative colitis (UC). Despite a growing number of available therapeutic options for UC, up to 50% of patients do not respond to initial treatment or lose response over time, highlighting the need for novel therapies. The IL-23 pathway has emerged as an important therapeutic target for UC. Mirikizumab is the first drug of its kind to receive approval for UC in Europe.
Meeting Abstract
Gastroenterology & Hepatology
R. Panaccione, I. Dotan, M. Ferrante, S. Danese, P. Bossuyt, K. Kligys, E. Neimark, J. Zambrano, X. Liao, G. D'Haens
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire
Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Correction
Gastroenterology & Hepatology
William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes
JOURNAL OF CROHNS & COLITIS
(2023)